Can NSAID Diclofenac Prevent Ophthalmopathy in Patients With Graves’ Disease?
October 27, 2011
A researcher at Skane University Hospital in Sweden will be undertaking a study to investigate if the NSAID diclofenac can prevent ophthalmopathy and/or progress of ophthalmopathy in patients with Graves’ disease.
The study will look at (i) the frequency of clinical ophthalmopathy in Graves´ disease after 12 months treatment with or without diclofenac, (ii) the frequency of progress of clinical signs and symptoms in ophthalmopathy after 12 months treatment with or without diclofenac, and (iii) the frequency of optic neuropathy in clinical ophthalmopathy after 12 months treatment with or without diclofenac.
150 patients with newly diagnosed Graves´disease without ophthalmopathy will be treated with anti-thyroid drugs and L-thyroxin (block and replace) according to clinical routine for 18 months. These patients will be randomized to diclofenac 50 mg twice daily or not for 12 months.
Click here for further details.
Jump down to form below to submit your own comments